NASDAQ:NCNA

NuCana Q4 2024 Earnings Results & Report

NuCana logo
$0.88 +0.02 (+1.96%)
Closing price 03:55 PM Eastern
Extended Trading
$0.87 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$64.00 versus the -$486.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens

NuCana EPS Results

Actual EPS
-$64.00
Consensus EPS
-$486.00
Beat/Miss
Beat by +$422.00
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NuCana Q4 2024 Earnings FAQ

NuCana (NASDAQ:NCNA) reported earnings of -$64.00 per share for Q4 2024, beating the consensus estimate of -$486.00. The report was announced on Thursday, March 20, 2025.

NuCana Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
NuCana plc Sponsored ADR
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, that develops investigational medicines for cancer. Its research focuses on nucleotide analogues, a class of compounds used in some cancer treatments.

The company’s ProTide platform is designed to improve how these compounds enter cells and become active. NuCana’s development programs have included NUC-3373, an investigational fluoropyrimidine, and NUC-7738, an investigational adenosine analogue, as well as NUC-1031, an earlier candidate.

NuCana’s work is centered on developing and evaluating potential cancer therapies; its drug candidates are investigational and have not been established as approved treatments.

View NuCana Profile